|
Synonyms: rhC1INH | Ruconest®
conestat alfa is an approved drug (EMA (2010), FDA (2014))
Compound class:
Peptide or derivative
Comment: Conestat alfa is a recombinant analogue of the human C1 esterase inhibitor produced by recombinant DNA technology (in transgenic rabbits). The protein sequence of the enzyme peptide chain is identical to the endogenous human enzyme encoded by the SERPING1 gene (P05155) [1], but it lacks the 22 amino acid signal peptide.
Three nanofiltered/virus filtered, pasteurized, human plasma–derived C1 esterase inhibitor concentrates are already approved by international approval agencies; Berinert® (eMC link), Cetor® (available in the Netherlands and Turkey) and Cinryze® (EMA link). |
| No information available. |
Summary of Clinical Use  |
| This drug is used to treat acute angioedema attacks in adults with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency (OMIM:106100). COVID-19: Conestat alfa is being investigated for the prevention of severe disease in COVID-19 patients, and for potential to improve post-infection neurological symptoms. |
| Mechanism Of Action and Pharmacodynamic Effects |
| Conestat alfa acts as an enzyme replacement therapy. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04530136 | Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19 | Phase 2 Interventional | Pharming Technologies B.V. | ||
| NCT04705831 | Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection | Phase 4 Interventional | IMMUNOe Research Centers | ||
| External links |
|
For extended ADME data see the following: Electronic Medicines Compendium (eMC) European Medicines Agency (EMA) |
